Gastrointestinal tumours
Invited discussant abstracts 148PD, 149PD and 150PD
Date
20 Dec 2015Session
Gastrointestinal tumoursPresenters
Jean-Yves DouillardAuthors
J. DouillardAuthor affiliations
- Oncologie Médicale, Centre Rene-Gauducheau, 44805 - Nantes-Saint-Herblain/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
View the abstracts discussed:
- Pattern of regional recurrence after curative resection in adenocarcinoma of oesophagogastric junction: Implication for elective lymphatic target definition of radiotherapy
- Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI + cetuximab every other week in the APEC study
- Discordant RAS status between primary and metastatic colorectal cancer and predicted pattern of metastases
Resources from the same session
What is the interventional treatment in HCC?
Presenter: Pierce Chow
Session: Gastrointestinal tumours
Resources:
Slides
Webcast
434 - TACE with sorafenib for recurrent hepatocellular carcinoma: a retrospective nested case-control study
Presenter: Xuying Wan
Session: Gastrointestinal tumours
Resources:
Abstract
1340 - Pattern of regional recurrence after curative resection in adenocarcinoma of oesophagogastric junction: Implication for elective lymphatic target definition of radiotherapy
Presenter: Jiajia Zhang
Session: Gastrointestinal tumours
Resources:
Abstract
Invited discussant abstracts 146PD and 147PD
Presenter: Pierce Chow
Session: Gastrointestinal tumours
Resources:
Slides
Webcast
How can we predict success in anti-EGFR?
Presenter: Eric van Cutsem
Session: Gastrointestinal tumours
Resources:
Slides
Webcast
317 - Ginsenoside Rg3 improves transarterial chemoembolization treatment in Chinese patients with advanced hepatocellular carcinoma
Presenter: BO Zhou
Session: Gastrointestinal tumours
Resources:
Abstract
1041 - Discordant RAS status between primary and metastatic colorectal cancer and predicted pattern of metastases
Presenter: KIN SANG Lau
Session: Gastrointestinal tumours
Resources:
Abstract
758 - Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI + cetuximab every other week in the APEC study
Presenter: Ann-Lii Cheng
Session: Gastrointestinal tumours
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.